PMID- 18208411
OWN - NLM
STAT- MEDLINE
DCOM- 20080725
LR  - 20080505
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 48
IP  - 5
DP  - 2008 May
TI  - Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells 
      generated from blasts of patients with acute myeloid leukemia.
PG  - 861-70
LID - 10.1111/j.1537-2995.2007.01616.x [doi]
AB  - BACKGROUND: Dendritic cells (DCs) generated from leukemic blasts constitute a 
      promising tool in immunotherapy for acute myeloid leukemia patients (AML-DCs), 
      because AML-DCs express human leukocyte antigens and costimulatory molecules such 
      as CD40, CD80, and CD86 at a higher level than leukemic blasts. Potentiation of 
      AML-DC vaccine might become feasible by the addition of adjuvants such as 
      lipopolysaccharides (LPS) or CPG-rich oligodeoxyribonucleotides binding to 
      Toll-like receptors (TLR) and inducing a stronger Type 1 T-cell response. STUDY 
      DESIGN AND METHODS: mRNA and protein expression of TLR-2, -4, and -9 were 
      analyzed with quantitative real-time polymerase chain reaction, Western blot, and 
      flow cytometry for mature monocyte-derived DCs generated from 14 AML patients 
      versus 14 healthy volunteers (HV-DCs), and the response of the AML- and HV-DCs to 
      different microbial TLR ligands was determined by enzyme-linked immunosorbent 
      assay for the proinflammatory cytokines tumor necrosis factor (TNF)-alpha, 
      inducible protein (Ip)-10, and interleukin (IL)-6. RESULTS: AML-DCs and HV-DCs 
      strongly expressed TLR-2 and TLR-4, while TLR-9 was expressed at a lower level in 
      both groups. There was no significant difference in TLR expression between the 
      two groups of AML-DCs and HV-DCs. In accordance with the TLR expression levels, 
      DCs generated from both AML patients and HVs responded to the known microbial 
      ligands peptidoglycan (PGN) and lipoteichoic acid for TLR-2 and LPS as ligand for 
      TLR-4, by producing TNF-alpha and IL-6. A response to the ODNs 2006 and 2216 
      binding to TLR-9 was only detected in AML-DCs. CONCLUSION: Microbial ligands like 
      ODNs and LPS constitute promising adjuvants for enhancing (AML-) DC vaccines.
FAU - Schmitt, Anita
AU  - Schmitt A
AD  - Institute for Clinical Transfusion Medicine and Immunogenetics (IKT) gGmbH Ulm, 
      University of Ulm, Ulm, Germany.
FAU - Li, Li
AU  - Li L
FAU - Giannopoulos, Krzysztof
AU  - Giannopoulos K
FAU - Greiner, Jochen
AU  - Greiner J
FAU - Reinhardt, Peter
AU  - Reinhardt P
FAU - Wiesneth, Markus
AU  - Wiesneth M
FAU - Schmitt, Michael
AU  - Schmitt M
LA  - eng
PT  - Journal Article
DEP - 20080115
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 0 (Peptidoglycan)
RN  - 0 (RNA, Messenger)
RN  - 0 (TLR2 protein, human)
RN  - 0 (TLR4 protein, human)
RN  - 0 (TLR9 protein, human)
RN  - 0 (Toll-Like Receptor 2)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Toll-Like Receptor 9)
RN  - 0 (Toll-Like Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cancer Vaccines
MH  - Cytokines/metabolism
MH  - Dendritic Cells/drug effects/*physiology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Expression Regulation, Leukemic
MH  - Humans
MH  - Immunophenotyping
MH  - Immunotherapy/*methods
MH  - Leukemia, Myeloid, Acute/immunology/*physiopathology/*therapy
MH  - Leukocytes, Mononuclear/drug effects/physiology
MH  - Lipopolysaccharides/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Oligodeoxyribonucleotides/pharmacology
MH  - Peptidoglycan/pharmacology
MH  - RNA, Messenger/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Toll-Like Receptor 2/genetics/metabolism
MH  - Toll-Like Receptor 4/genetics/metabolism
MH  - Toll-Like Receptor 9/genetics/metabolism
MH  - Toll-Like Receptors/*genetics/metabolism
EDAT- 2008/01/23 09:00
MHDA- 2008/07/26 09:00
CRDT- 2008/01/23 09:00
PHST- 2008/01/23 09:00 [pubmed]
PHST- 2008/07/26 09:00 [medline]
PHST- 2008/01/23 09:00 [entrez]
AID - TRF01616 [pii]
AID - 10.1111/j.1537-2995.2007.01616.x [doi]
PST - ppublish
SO  - Transfusion. 2008 May;48(5):861-70. doi: 10.1111/j.1537-2995.2007.01616.x. Epub 
      2008 Jan 15.